Why Contract Research Organizations Are Racing to Build a Single Path Through Asia

The Asia-Pacific clinical trials market was worth roughly $16.8 billion in 2024 and is on pace to more than double by the early 2030s, growing faster than any other region as sponsors look for cheaper, faster, more diverse trial populations than North America or Europe can offer. Government incentives, regulatory reform and a wave of pharma R&D outsourcing are all pushing in the same direction, and the region’s share of global trial activity keeps climbing.

That growth has set off a fairly predictable scramble among contract research organizations, the outsourced vendors that run trials on behalf of biotech and pharma sponsors. Rather than compete site-by-site or country-by-country, several CROs are now trying to package Australia, Taiwan, South Korea and a handful of Southeast Asian and Chinese markets into a single, sellable pipeline — pitching themselves as the one vendor a sponsor needs from first-in-human data through late-phase, multi-country enrollment. Adelaide-based Avance Clinical is one of the more visible companies making that pitch this year, and its recent moves double as a decent case study for what the strategy actually looks like up close.

The Australian On-Ramp — and Who Else Is Selling It

The starting point for nearly every version of this pitch is the same: Australia’s early-phase regulatory pathway. Under Avance Clinical’s GlobalReady model, a sponsor can move from a final protocol to human research ethics committee (HREC) approval in roughly five to six weeks, without first holding an open Investigational New Drug (IND) application — a prerequisite that can take considerably longer to clear through the FDA. Data generated under the Therapeutic Goods Administration (TGA) framework is accepted by the FDA, the EMA and other major regulators, so an Australian first-in-human study doesn’t have to be redone once a program moves toward a US or European filing. Layer on a 43.5% rebate on qualifying R&D expenditure, and it’s easy to see why the country has become a default early-phase destination for capital-constrained biotechs.

None of that is exclusive to Avance Clinical, though, and it’s worth saying so plainly. Sydney-based Novotech — a considerably larger CRO with roughly 550 employees and offices across 11 Asia-Pacific countries — has been running an almost identically named “Australian Advantage” pitch for years, citing the same five-to-six-week HREC timeline and the same R&D rebate. Novotech was also exhibiting at BIO Asia-Taiwan this year, making essentially the same case to essentially the same pool of sponsors. The regulatory advantage is real, but it’s a shared asset of the Australian system, not a proprietary edge any one CRO can claim.

What actually differentiates these companies, then, isn’t the on-ramp — it’s what happens after a sponsor’s Australian data comes back and the program needs somewhere to go for later-phase, patient-heavy trials.

Taiwan’s Hospital Network Is the More Interesting Story

That’s where Avance Clinical’s Taiwan partnerships come in, and they’re a more specific asset than the Australian pitch. In March 2025, the company signed memoranda of understanding with four hospitals: Taipei Medical University, China Medical University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, and Taichung Veterans General Hospital (TCVGH). Of the four, TCVGH gets the most airtime in the company’s own materials, largely because of its CAR-T cell therapy program — dean Prof. Yun-Ching Fu has pointed to it as one of Taiwan’s higher-volume sites for treated CAR-T cases, which matters to sponsors running later-phase oncology and cell-therapy trials that need both specialized infrastructure and enough patients to hit enrollment targets on schedule.

It’s worth a note of caution here, since it applies to nearly every hospital partnership a CRO announces: an MOU is not a signed trial. It’s a framework agreement — a statement of intent to work together — and the actual value only shows up once specific sponsors run specific studies through those sites. Plenty of CRO-hospital MOUs across the industry are announced with fanfare and then quietly generate a handful of trials, or none, depending on how well the CRO actually converts the relationship into sponsor business. There’s no public data yet on how many trials have moved through the Taiwan network since the MOUs were signed, which makes it hard to judge from the outside whether the partnership is delivering the volume it was pitched on.

What the network does solve, at least in principle, is a real operational headache: continuity. A sponsor moving from an Australian Phase I into a Taiwan-anchored Phase II ideally keeps the same protocol, the same data standards and largely the same CRO team managing both ends, avoiding the redundant assay validation and mismatched documentation that tend to slow down trials run across separate, disconnected vendors.

A Build-Out That’s Still Mostly on Paper

Beyond Australia and Taiwan, Avance Clinical spent much of this year announcing a wider Asia-Pacific footprint: dedicated clinical operations teams in Singapore and Malaysia, a scale-up of existing operations in India — where it already maintained a business presence and a biometrics hub — and newly appointed Business Development Directors in Shanghai and Beijing to court mainland Chinese sponsors. Jessica Han, the company’s Director of Asian Operations, has described the logic as connecting pieces that used to sit apart: each APAC market carries its own regulatory framework and patient population, and a sponsor navigating them one country at a time loses time it can’t afford to lose.

But it’s worth reading that expansion at the resolution it was actually announced, rather than the resolution the press releases suggest. “Business Development Directors” in Shanghai and Beijing is a sales presence, not a clinical operations footprint — a meaningfully lighter commitment than the “dedicated clinical operations teams” language used for Singapore and Malaysia, which itself signals those teams are still being built rather than already running trials. India is described as being “scaled up” from an existing base, which is more concrete, but still short of the fully operational network the company’s marketing language implies.

None of that makes the expansion hollow — plenty of legitimate corporate growth starts with a regional hire before it becomes a functioning office. But the gap between “we’ve expanded into six markets” and “we can run a trial in six markets tomorrow” is exactly the kind of distinction that tends to get flattened in CRO press coverage, and sponsors doing real diligence would be right to ask which side of that gap any specific market actually sits on before committing a program to it.

A Crowded, Consolidating Field

It’s also worth sizing Avance Clinical against the field it’s competing in, because the framing of “leading CRO” gets thrown around loosely in this industry. Globally, IQVIA leads the clinical trials market with roughly 14% share, and the broader field includes considerably larger, longer-established players — ICON, WuXi AppTec, Charles River, Fortrea, Tigermed — most of which already run multi-country Asia-Pacific operations. Regionally, Novotech alone has been operating across 11 Asia-Pacific countries for years, with a scale that dwarfs the six-market footprint Avance Clinical announced this year. Avance Clinical is a genuine, credentialed player in the early-phase Australian niche, but the recent expansion reads less like a company breaking new ground and more like one catching up to a playbook its larger regional competitor has run for some time.

That context matters for how much weight to put on the industry recognition Avance Clinical picked up this year. In May, Frost & Sullivan named the company its 2026 Global Company of the Year in the biotechnology CRO category, based on the firm’s benchmarking of strategy effectiveness and execution rather than trial volume, revenue or head-to-head market share. Industry awards of this kind are common in the CRO space — most major players collect several a year from various research and advisory firms — and they function more as a marketing asset than an independent verdict on competitive standing. That doesn’t make the recognition meaningless, but it’s a different thing than evidence the company has pulled ahead of Novotech, IQVIA, or any of the larger names it’s ultimately competing against for the same sponsor dollars.

What It Means for the Region

Step back from any single company, and the more durable story here is the one about the region itself. Asia-Pacific’s growth as a clinical trials market isn’t a marketing narrative — it’s backed by real numbers, real regulatory reform (Taiwan, for instance, recently cut its own first-in-human approval timeline by roughly three months), and real demand from sponsors trying to diversify away from an increasingly expensive and uncertain US trial environment. That underlying shift is what’s pulling CROs of every size toward the same consolidated, multi-country pitch, whether the company making it is Avance Clinical, Novotech, or one of the global giants.

For sponsors evaluating any of these pitches, the practical takeaway is to separate the parts of the story that are structural — Australia’s regulatory speed, Taiwan’s hospital infrastructure, the region’s overall growth trajectory — from the parts that are specific to one CRO’s current capacity to deliver on them. The first category is genuinely durable and worth taking seriously. The second is worth diligencing hospital by hospital, market by market, before assuming an announced footprint is the same thing as an operational one.

Author

Michelle Jessica